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Abstract: Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the 
central nervous system. It frequently affects females in their reproductive phase of life.  Therefore, 
family planning, pregnancy, and breastfeeding are important issues in the management of MS, 
particularly with respect to counseling and drug treatment. This paper reviews currently avail-
able data on the outcome of pregnancies in MS patients and the influence of pregnancy on the 
course of the disease. We give an update on the use of various disease-modifying MS drugs 
during pregnancy and breastfeeding. In addition to established therapies such as interferon-β, 
glatiramer acetate, natalizumab, and fingolimod, we also discuss the state of knowledge about 
new agents such as dimethyl fumarate, teriflunomide, and alemtuzumab in the context of preg-
nancy and breastfeeding.
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Introduction
Multiple sclerosis (MS) is the most common chronic inflammatory disorder of the 
central nervous system during young adulthood.1 Simplified infiltration of autoreactive 
lymphocytes leads to the formation of inflammatory plaques in the brain and spinal 
cord characterized by demyelination and neurodegeneration, which result in transient 
neurologic dysfunction. Thereafter, diffuse axonal and neuroaxonal degeneration leads 
to an ongoing accumulation of neurologic deficits. Both genetic and environmental 
factors are considered to be involved in the pathogenesis of MS.1 Women are more 
frequently affected than men. In some regions, especially in countries of northern 
latitude, the male to female ratio is as high as 1:4.5.2–4 Because many MS patients are 
of fertile age, family planning and pregnancy can become relevant issues during the 
disease course.
Reasonably, many women with MS who plan to conceive or are already pregnant 
consult their obstetrician for advice. Unfortunately, obstetricians are not usually 
experienced in MS. Conversely, many neurologists have only limited knowledge of 
obstetrics and pregnancy in MS.5 For this reason, it may be difficult for MS patients 
to get competent advice on the influence of MS on pregnancy, birth, and lactation, or 
on the effect of pregnancy on the MS disease course.
This paper summarizes current knowledge on the influence of pregnancy and 
 lactation on MS and addresses the question of whether having MS influences the course 
and outcome of pregnancy. In particular, we give an overview of current recommenda-
tions on the use of disease-modifying drugs (DMDs) during pregnancy and lactation. 
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Further pregnancy-related issues, such as inheritance risk, 
fertility, and reproduction techniques, are beyond the scope 
of this paper and are addressed elsewhere.6,7
Influence of pregnancy on MS
Numerous studies have investigated the influence of pregnancy 
on the MS disease course. In 1998, the PRIMS  (Pregnancy in 
Multiple Sclerosis) study examined the course of 269 pregnan-
cies in 254 MS patients in a prospective manner.8 The authors 
showed that the relapse rate decreases during pregnancy and 
reaches a nadir in the third trimester. However, in the first 
months after delivery, the relapse rate increased to a higher 
level than before pregnancy. Six to 9 months after delivery, the 
relapse rate decreased to prepregnancy rates. Further studies 
subsequently confirmed these results.9,10 Whether relapses in 
the year before and during pregnancy represent a risk factor 
for postpartum relapse is not yet conclusive.11,12
The immunologic mechanisms responsible for the 
decrease in disease activity during pregnancy are still poorly 
understood. It is supposed that immunologic changes aimed 
at protecting the fetus from maternal immune defense 
contribute to the observed reduction in disease activity. 
A T-helper 1 to T-helper 2 cell shift is often discussed in the 
literature,13,14 although current data suggest that the mecha-
nisms are more complex. Changes in CD56bright natural killer 
cells,14 interferon gamma (IFN-γ)-producing CD4+ T-cells,15 
in the CD4+/CD8+-ratio,16 and in interleukin-8 serum levels17 
have been described during pregnancy. Moreover, regulatory 
T-cells seem to play an important role in modulating disease 
activity during pregnancy in MS.18–21 Further studies are nec-
essary to investigate the underlying cellular and molecular 
mechanisms.
Influence of MS on pregnancy  
and childbirth
Many female MS patients are concerned that the disease 
may have a negative impact on pregnancy or childbirth. In 
2011, a meta-analysis evaluated the results of 22 studies 
between 1983 and 2009, and included a total of more than 
13,000 pregnancies in mothers with MS.22 The rates of abor-
tion, prematurity, malformation, and neonatal death in MS 
patients were comparable with those in healthy mothers. 
Although some surveys revealed a slight reduction in birth 
weight of between 108 g and 123 g,23,24 an elevated risk of 
low birth weight (,2,500 g) in newborns of MS mothers was 
not detected in the meta-analysis.22 Another survey studying 
432 births in 321 MS patients showed no differences in birth 
weight, mean gestational age, labor duration, or 5-minute 
Apgar score.25 Except for a higher rate of maternal anemia, no 
other pregnancy-related complications, including gestational 
diabetes mellitus or preeclampsia, were recorded.26
In healthy women, rates of primary cesarean section in 
various countries show great variability and are influenced 
by religious, social, and cultural values. It is therefore not 
surprising that cesarean delivery in MS mothers shows wide 
regional differences, ranging from 10% to 40%.22 Some 
 studies found no elevated rates of cesarean section in MS,25,26 
whereas others revealed a higher rate of cesarean delivery 
when compared with the general population.23,27 Importantly, 
the higher rate of cesarean section in MS was due to an 
increase in planned and not emergency deliveries.23
On the one hand, a cesarean section may in fact be ben-
eficial because it can be performed electively; there is no 
pain during childbirth, and the risks of retained placenta and 
urinary incontinence are lower. On the other hand, a cesarean 
delivery carries a greater risk of injury to the uterus, bladder, 
or ureter, and longer hospitalization. Many MS patients and 
physicians may favor a cesarean section as they are concerned 
that spasticity, neuromuscular perineal weakness, or exhaus-
tion in the context of MS could complicate a natural delivery. 
In rare cases, these may actually be reasons for planning an 
elective cesarean section. However, given that the number of 
emergency cesarean sections in MS does not exceed that in 
healthy women, the fact alone of suffering from MS should 
not, in our opinion, be a reason to choose cesarean section 
over vaginal delivery if no other obstetric reasons exist.
Some surveys have revealed higher rates of operative 
delivery with the use of forceps or vacuum extraction in 
MS patients23,26,28 due to exhaustion and slow progression 
of delivery. MS patients should therefore be informed about 
these issues. In 1998, Confavreux et al found no impact of 
epidural analgesia on the postpartum relapse rate in MS.8 
Another study in 2012 confirmed these results.29 MS patients 
should therefore be advised that MS per se is no reason to 
abstain from epidural analgesia.
Disease-modifying drugs  
during pregnancy
Over approximately 25 years, an increasing number of 
drugs have been made available for immunomodulatory 
therapy in MS. The most experience is with interferon beta 
(IFN-β) and glatiramer acetate (GA), which are administered 
 subcutaneously. In patients with adverse effects or high dis-
ease activity, escalation with intravenous natalizumab once 
a month or orally administered fingolimod, a sphingosine 
receptor modulator, is feasible. For patients with secondary 
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progressive MS, mitoxantrone is a possible treatment option. 
Recently, teriflunomide, dimethyl fumarate (DMF), and 
alemtuzumab have been made available as further therapy 
options in relapsing–remitting MS.
Managing DMDs in the context of conception and preg-
nancy poses a challenge for both MS patients and attending 
physicians. On the one hand, unnecessary risks to the child 
should be avoided; on the other, patients left without medica-
tion are subject to a higher risk of MS relapse. To date, none of 
the DMDs available for MS has been approved for use during 
pregnancy. The current data are primarily derived from MS 
pregnancy registries and are often collected retrospectively. 
Therefore, it is difficult to give evidence-based recommenda-
tions for MS treatment during pregnancy. The United States 
Food and Drug Administration (FDA) pregnancy categories 
can be used as a reference for decision-making (Table 1). 
According to that classification, GA is considered to be the 
safest of the currently available MS drugs. It is assigned to 
category B, whereas IFN-β, natalizumab, and fingolimod are 
classified one category lower. We describe in detail below 
the data currently available for the different drugs and their 
use during pregnancy.
intravenous methylprednisolone
Relapses in MS are commonly treated with high-dose meth-
ylprednisolone given intravenously on 3–5  consecutive days. 
Glucocorticoid therapy accelerates recovery, but does not 
Table 1 US Food and Drug Administration pregnancy categories
FDA pregnancy  
category
Description Drug
B Animal studies have revealed no evidence of harm to the fetus; however, there are no adequate  
and well controlled studies in pregnant women. 
OR 
Animal studies have shown an adverse effect, but adequate and well controlled studies in pregnant  
women have failed to demonstrate a risk to the fetus in any trimester.
Glatiramer acetate
C Animal studies have shown an adverse effect and there are no adequate and well controlled studies  
in pregnant women. 
OR 
No animal studies have been conducted and there are no adequate and well-controlled studies  
in pregnant women.
iFN-β 
Natalizumab 
Fingolimod 
Dexamethasone 
Prednisolone 
iviG 
Dimethyl fumarate 
Cyclosporin A
D Adequate well controlled or observational studies in pregnant women have demonstrated a risk to the  
fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be  
acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be  
used or are ineffective.
Cyclophosphamide 
Azathioprine 
Mitoxantrone
X Adequate well controlled or observational studies in animals or pregnant women have demonstrated  
positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women  
who are or may become pregnant.
Methotrexate 
Teriflunomide
Abbreviations: iviG, intravenous immunoglobulin G; FDA, US Food and Drug Administration; iFN-β, interferon beta.
seem to have an impact on the level of remission finally 
achieved.30
Methylprednisolone is classified within category C by 
the FDA (Table 1). The manufacturers indicate that during 
pregnancy, especially in the first trimester, methylpredni-
solone should be used only after a thorough risk–benefit 
analysis. Animal studies showed higher risks of cleft palates 
and intrauterine growth disturbances. Adequate studies in 
human pregnancy are lacking.
An elevated risk of oral clefts has been described in 
pregnant women suffering from inflammatory bowel disease, 
bronchial asthma, or lupus erythematosus who were given 
glucocorticoids during the first trimester.31 Another study 
showed lower gestational age, decreased birth weight, and 
higher rates of miscarriage after exposure to glucocorti-
coids in the first trimester.32 In light of these findings, we 
recommend discussing the use of glucocorticoids during 
the first 3 months of pregnancy very critically. Use of such 
medication during this period should be reserved for severe 
MS relapses. Treatment with glucocorticoids during the 
second and third trimesters does not seem to be harmful 
to the fetus.33
interferon beta
Since the mid-1990s, IFN-β has been approved for subcuta-
neous or intramuscular immunomodulatory therapy of MS. 
IFN-β leads to a reduction in relapse rate of approximately 
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30%34 and decreases the progression of disability in long-
term follow-up.35
The FDA classifies IFN-β within category C because 
animal studies have shown adverse effects on the fetus, 
and no adequate studies in pregnant women exist (Table 1). 
According to the German manufacturing information, it 
is explicitly contraindicated to start IFN-β therapy during 
pregnancy due to a potentially elevated risk of spontaneous 
abortion. Patients with a high relapse rate who are already 
undergoing treatment with IFN-β are advised to weigh the 
risk of severe relapse after discontinuation of IFN-β against 
the risk of spontaneous abortion.
Currently, IFN-β can be considered the DMD with the 
largest experience of use in pregnant women with MS. In the 
literature, data from approximately 1,000 pregnancies with 
IFN-β exposure at the time of conception and at least the first 
weeks of pregnancy are currently available. Table 2 provides 
an overview of a number of studies on birth outcome after 
exposure to IFN-β. In 2012, a systematic review by Lu et al 
summarized the results of several studies on the safety of 
DMDs during pregnancy.36 A total of 761 pregnancies with 
IFN-β exposure were included. The authors associated IFN-β 
exposure with preterm birth as well as lower birth weight and 
length. However, no elevated risks of spontaneous abortion, 
birth weight under 2,500 g, cesarean section, or congenital 
abnormalities were described.
Some authors, including Lu et al,35,36 advise women to 
discontinue DMD when they plan to conceive. In contrast, 
Schröder and Schilli point out that since June 2006 an 
IFN-β treatment-free interval before a planned pregnancy 
is no longer recommended by the European Medicines 
Agency.37 Based on the data currently available, intake of 
IFN-β during the conception period and the first weeks of 
pregnancy seems to be relatively safe. It has become increas-
ingly common to continue IFN-β until pregnancy has been 
confirmed. Given that it is not known when gestation will 
start, this approach seems to be justified, particularly in 
patients with high disease activity. However, continuation 
of IFN-β treatment throughout pregnancy should be consid-
ered very carefully. Only a small number of cases involving 
IFN-β therapy over the course of the entire pregnancy is 
available in the current literature.38,39 In these studies, all 
Table 2 Studies on birth outcome after exposure to interferon beta
Year Authors Pregnancies (n) Results
2005 Boskovic et al84 23 increased rate of spontaneous abortion (39%); decreased birth weight (∼3,190 g);  
two major birth defects (Down syndrome, X chromosome abnormality)
2005 Sandberg- 
wollheim et al85
41 Normal spontaneous abortion rate, one birth defect (hydrocephalus)
2008 Patti et al86 14 Normal spontaneous abortion rate; normal birth weight; shorter gestational period  
(37.8 weeks), no malformations
2009 Hellwig et al87 17 Normal miscarriage rate (12%), normal birth weight
2009 weber-Schoendorfer 
and Schaefer44
69 Higher rate of spontaneous abortion for iFN-β1b (28%) compared with iFN-β1a (5%) but 
normal spontaneous abortion rate in combined iFN-β cohort; lower birth weight (∼2,330 g)
2010 Amato et al88 88 Lower birth weight (∼3,000 g); decreased birth length (∼49 cm); higher rate of preterm  
delivery (33% versus 20%); normal rate of spontaneous abortion; no major birth defects
2010 Coyle et al89 69 Normal spontaneous abortion rate; three birth defects (trisomy 21, multiple hemangiomas, 
cardiovascular defect, and hip dysplasia)
2011 Sandberg- 
wollheim et al90
425 Normal spontaneous abortion rate; three major birth defects (vACTeRL syndrome,  
Tetralogy of Fallot, solitary kidney)
2011 Finkelsztejn et al10 69 One case of delayed intrauterine growth; two malformations (Dandy-walker-syndrome, 
ventriculomegaly); two cases of neonatal jaundice
2011 Hellwig and Gold38 7 exposure throughout pregnancy; normal birth weight; no preterm delivery;  
one malformation (valvular stenosis of pulmonary artery)
2012 Lu et al48 15 Trend to higher risk for assisted vaginal delivery; normal rate of cesarean section;  
normal birth weight gestational age and Apgar score; no congenital abnormalities
2012 Richman et al91 298 30 spontaneous abortions; 27 birth defects (no details given)
2012 Hellwig et al50 78 Normal birth weight and length; three birth defects (ventricular septal defect, valvular  
stenosis of the pulmonary artery, hip dysplasia)
2013 Fragoso et al49 17 Normal rate of obstetric complications; lower birth weight (∼2,760 g) and length (∼47 cm);  
lower postpartum relapse rate and eDSS progression in women with .8 weeks of exposure 
during pregnancy
2014 Dung and Panda39 1 exposure throughout pregnancy; normal birth weight; no congenital anomaly
Abbreviations: EDSS, Expanded Disability Status Scale; IFN, interferon; VACTERL, Vertebral anomalies, Anal atresia, Cardiac defects, Tracheoesophageal fistula and/or 
esophageal atresia, Renal & Radial anomalies and Limb defects.
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patients delivered newborns of normal birth weight and 
gestational age.  However, one baby had valvular stenosis of 
the pulmonary artery. The causal relationship between this 
malformation and intrauterine IFN-β exposure is not clear. 
Obviously, these data are not sufficient to make any therapy 
recommendations.
Glatiramer acetate
GA was approved in 1996 as a DMD for relapsing-remitting 
MS in the USA, and European Union approval was granted 
5 years later. GA reduces the MS relapse rate by approxi-
mately 30%40 and the number of enhancing magnetic reso-
nance imaging (MRI) lesions to the same extent.41 Moreover, 
a 45% risk reduction in conversion from clinically isolated 
syndrome to clinically definite MS was reported in the Pre-
CISe study (ClinicalTrials.gov identifier NCT00666224).42
According to the FDA classification (Table 1), GA is 
considered the safest DMD during pregnancy in MS. This 
classification is based on there being no evidence of fetal 
harm in animal studies, although adequate and well con-
trolled studies in pregnant women are lacking. Compared 
with IFN-β, considerably fewer studies exist with respect 
to safety during pregnancy. In the pivotal clinical trials and 
post-marketing period until 2003, 250 pregnancies were 
recorded. The rates of spontaneous abortions and major 
congenital anomalies were described to be in the range 
of the general population.43 In addition, approximately 
200 pregnancies under treatment with GA are described in 
the literature. These studies revealed a normal spontaneous 
abortion rate,44–47 mean birth weight,10,44–50 and gestational 
age.10,44,47,48,50 Some studies, however, described preterm 
delivery,38 one case of neonatal death,49 and a reduction in 
birth weight38 and length.49 Reported congenital anomalies 
were, for example, penile hypospadias,38 clubfoot,44 atrioven-
tricular canal defects,44 bone malformations,49 abnormality of 
urinary bladder valves,50 and hip dysplasia.50 However, the 
number, severity, and nature of congenital malformations did 
not exceed the range expected in the general population.
Whether GA should be discontinued before a planned 
conception is controversial in the literature. In light of the 
limited data, some authors recommend discontinuation 
as soon as conception is planned,36 whereas others cau-
tion against leaving patients untreated while waiting for 
conception.51
In line with most expert opinion and guidelines, and similar 
to the approach with IFN-β, we recommend patients continue 
treatment with GA until pregnancy has been confirmed, par-
ticularly in patients with a high relapse rate before pregnancy. 
In any case, the possible risks and benefits have to be weighed 
individually, taking into account the viewpoint of the patient 
and lack of available data at present.
Natalizumab
Natalizumab is a monoclonal antibody used in the treat-
ment of MS patients with high disease activity and those in 
whom IFN-β or GA has had an insufficient effect. Studies 
have shown a reduction in the annualized relapse rate of up 
to two thirds52,53 and a significant reduction in gadolinium-
enhancing lesions.53,54
The largest data collection on pregnancy outcome 
after exposure to natalizumab comes from the Tysabri® 
 (natalizumab) Pregnancy Exposure Registry.55 More than 
350 pregnancies with exposure to natalizumab within 90 days 
prior to the last menstrual period were followed. In 28 of 
these pregnancies, major and/or minor birth defects were 
observed, which is comparable with the rate detected by 
active birth registries in the general population.56 The rate 
of spontaneous abortion corresponded to the frequency in 
the general population.
Apart from this registry, approximately 40 patients 
receiving treatment with natalizumab during pregnancy 
are described in the literature.57–60 In two of the studies, 
natalizumab was continued until the third trimester or even 
throughout the pregnancy.59,60 These studies reported normal 
rates of spontaneous abortion and congenital malformation, 
and normal birth weight and length. Another case report 
described normal Apgar score, birth weight and length, and 
head circumference in two newborns with mothers who 
took natalizumab until week 34 of pregnancy.61 However, 
a reduction in CXCL12-induced T-cell chemotaxis was 
found in both of these children, which might compromise the 
neonatal immune system and be associated with an increased 
risk of infection.
Compared with IFN-β and GA, it is even more difficult to 
give advice about treatment with natalizumab in the context 
of a planned pregnancy. On the one hand, until now, there 
has been no conclusive evidence for an increased risk of 
adverse pregnancy outcomes. Moreover, discontinuation of 
natalizumab in the context of a planned pregnancy carries 
the risk of a rebound of disease activity.62 On the other hand, 
the data currently available are insufficient to rule out rare 
complications. Therefore, treatment with natalizumab should 
be stopped at the latest when pregnancy has been detected. 
After carefully assessing the potential risks and benefits, 
continuing treatment around the time of conception or even 
pregnancy can be taken into consideration. In contrast with 
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IFN-β, the manufacturer of natalizumab does not rule out 
use of the drug during pregnancy when necessary due to the 
clinical condition of the patient.
Fingolimod
Fingolimod acts as a sphingosine receptor modulator and has 
been approved for highly active relapsing-remitting MS in 
Europe since March 2011. Compared with placebo, it leads 
to a decrease in the annualized relapse rate of more than 
50% and significantly reduces the number of gadolinium-
enhancing lesions seen on MRI.63 In animal studies, fin-
golimod showed teratogenic effects, with increased rates of 
visceral malformation, eg, persisting truncus arteriosus or 
ventricular septal defect. Further, fetal growth retardation 
and an increase in embryofetal mortality were observed. For 
this reason, the manufacturer’s information advises against 
becoming pregnant during and for up to 2 months following 
treatment with fingolimod, and to stop fingolimod therapy 
immediately when an unplanned pregnancy is detected.
The outcomes of 127 pregnancies from the clinical trials 
and post-marketing experience of fingolimod were presented 
at the European Committee for Treatment and Research 
in Multiple Sclerosis meeting in October 2012.64 In these 
pregnancies, 21 spontaneous and 40 induced abortions 
were reported. Five congenital anomalies and three other 
pregnancy abnormalities occurred. This corresponds to the 
expected frequency in the general population. Out of this 
cohort, 66 pregnancies with in utero exposure to fingolimod 
are currently published.65 To collect further data, a multina-
tional fingolimod pregnancy registry has been established.
Mitoxantrone
Mitoxantrone is an intercalating agent that leads to  disturbances 
in DNA synthesis and repair mechanisms. It is approved in 
Europe for progressive relapsing and secondary progressive 
MS. Mitoxantrone therapy may result in improvements of 
disability, changes in the ambulation index, and a reduction 
in the number of treated relapses.66
Mitoxantrone is known to be mutagenic. The FDA 
classifies mitoxantrone within category D because of the 
known risks to the fetus, but in individual cases the potential 
benefit may outweigh the risk. The manufacturer’s informa-
tion indicates that in the event of an unplanned pregnancy 
during treatment with mitoxantrone, genetic counseling 
should be provided. In the literature, two case reports 
describe the pregnancy outcome after in utero exposure 
to mitoxantrone in MS patients.67,68 In one case, restricted 
growth without evidence of congenital malformation was 
reported.67 The other study described a newborn with Pierre 
Robin sequence, a  congenital malformation with cleft palate, 
micrognathia, and glossoptosis attributable to mitoxantrone 
exposure.68 Both males and females are advised to wait at 
least 6 months after discontinuing mitoxantrone therapy 
before starting unprotected sexual intercourse. Moreover, 
before beginning treatment, male MS patients should be 
informed about the possibility of cryopreserving sperm.
Teriflunomide
Teriflunomide is another drug available for oral use in MS 
therapy. Teriflunomide is the active metabolite of leflunomide, 
and is used as a disease-modifying antirheumatic drug. By 
inhibiting mitochondrial dihydroorotate dehydrogenase, 
teriflunomide inhibits the de novo synthesis of pyrimidine 
and thus reduces cell proliferation. This results in a decrease 
in numbers of activated lymphocytes and leads to a reduction 
in MRI gadolinium-enhancing lesions and annualized relapse 
rate by nearly 30%.69
For leflunomide, which has structural similarities to 
teriflunomide, a study involving 64 pregnant women with 
rheumatoid arthritis showed no elevated risk of congenital 
malformation, preterm delivery, or reduction in birth weight.70 
Although teriflunomide has shown no negative effects on 
fertility in animal studies, there is evidence of reproductive 
toxicity. The only existing data on pregnancy outcomes in 
humans come from the global pharmacovigilance database 
held by the manufacturer. In that database, 83 pregnancies in 
female patients and 22 pregnancies in partners of male patients 
were recorded.71 These pregnancies were detected during par-
ticipation in teriflunomide clinical trials. The authors report 
29 induced and 13 spontaneous abortions in female patients. 
Among partners of teriflunomide-treated males, two induced 
abortions and one spontaneous abortion were described. No 
congenital malformations were observed, and birth weight 
and gestational age were within the normal range.
The manufacturer recommends a reliable method of con-
traception during treatment with teriflunomide and as long as 
the plasma level is higher than 0.02 mg/L. If an unplanned 
pregnancy occurs during treatment, accelerated elimination 
of teriflunomide by cholestyramine or charcoal is strongly 
advised. Due to the long half-life, it might otherwise take 
between 8 months and 2 years after stopping teriflunomide 
for the plasma level to reach values below 0.02 mg/L. The 
extent to which this approach actually reduces the risk of an 
adverse pregnancy outcome is not yet known.
In MS patients who are planning pregnancy, use of 
teriflunomide should be discontinued and the plasma 
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level assessed. If necessary, the teriflunomide level can be 
reduced by the measures mentioned above before starting 
unprotected sexual intercourse. If the plasma level is below 
0.02 mg/L in two measurements within an interval of 2 weeks, 
and a further safety interval of one and a half months is main-
tained thereafter, there should be no risk to the newborn.
Dimethyl fumarate
In February 2014, DMF was approved as a further oral MS 
drug in Europe. DMF reduces the annualized relapse rate 
by approximately 50% and leads to a significant decrease in 
contrast-enhancing lesions on MRI.55 The manufacturer’s 
information describes that, in animal studies, high doses of 
DMF led to fetal growth restriction and increased lethality, 
although fertility does not seem to be reduced. The outcome 
of 25 pregnancies in humans undergoing DMF therapy 
was presented at the 2013 annual meeting of the American 
Academy of Neurology.72 No increase in rates of spontane-
ous abortion or fetal malformation were reported. However, 
given that existing safety data are insufficient, DMF is not 
recommended for use during pregnancy.
Alemtuzumab
Alemtuzumab is a recombinant monoclonal antibody directed 
against CD52 on the cell surface of T and B lymphocytes. 
Alemtuzumab mediates immunosuppressive effects by deple-
tion and repopulation of white blood cells. Compared with 
IFN-β, it leads to a significant reduction in annualized relapse 
rates and contrast-enhancing MRI lesions.73,74 With an inter-
val of 1 year alemtuzumab is given on 5 and 3 consecutive 
days, respectively, followed by a mandatory safety monitor-
ing period of 48 months. Animal pregnancy studies showed 
a significant reduction in the number of viable fetuses and 
a higher number of animals with intrauterine deaths due to 
administration of alemtuzumab during pregnancy. Moreover, 
lower weight gain during gestation was observed.
The manufacturer indicates that within 30 days after each 
alemtuzumab treatment cycle, serum levels were low or even 
not detectable. However, females of childbearing age are 
advised to avoid pregnancy during and 4 months after each 
treatment period, because alemtuzumab is known to cross the 
placenta barrier. Data on pregnancies occurring during  clinical 
trials have not yet been published by the manufacturer.
Breastfeeding in MS
There is still insufficient knowledge on whether  breastfeeding 
influences the course of MS, and postpartum relapse rate 
in particular. The results of several studies have been quite 
controversial, in some cases showing protective effects75–77 
and in other cases showing no effects.8,78,79 A meta-analysis 
of 12 studies revealed a positive effect of breastfeeding on 
the relapse rate, although many factors may contribute to a 
bias in those studies.80 Some studies were carried out retro-
spectively; moreover, in some, nursing women already had a 
lower annualized relapse rate before pregnancy and were less 
frequently treated with DMD compared with patients who 
were not breastfeeding. In any event, the risk of postpartum 
relapse during lactation always has to be weighed critically 
against starting treatment with a DMD soon after delivery. 
In patients with a high risk of relapse, waiving DMD in favor 
of breastfeeding has to be considered carefully, whereas in 
patients with low disease activity it may be justifiable.
Medication for MS during lactation
None of the DMDs mentioned above has been approved 
for treatment of MS during lactation. Methylprednisolone 
is known to pass into breast milk. For this reason, many 
women are advised to wean their child when receiving glu-
cocorticoids for treatment of relapses. Nevertheless, there is 
a tendency to continue nursing despite cortisone therapy. If 
an interval of 4 hours between medication and breastfeeding 
is maintained, this approach seems to be reasonable.33 IFN-β 
and GA might be the safest DMDs to use during lactation 
because they have a high molecular weight and are not 
detectable to a relevant extent in breast milk.81 Natalizumab, 
fingolimod, and mitoxantrone are known to pass into breast 
milk and should not be used by breastfeeding women.  Animal 
studies have shown that teriflunomide and alemtuzumab 
pass into breast milk; for DMF there is no information on 
that issue available.
Fatherhood in patients with MS
Little is known about the course and outcome of pregnan-
cies fathered by men with MS. In 2010, the first study 
on pregnancy outcomes in MS fathers receiving disease-
modifying therapy (DMT) was published by Hellwig et al.82 
Compared with healthy mothers and MS mothers with and 
without DMT, no differences were found in birth weight and 
length. Recently, Lu et al published data on 202 pregnancies 
fathered by 141 men with MS.83 There were no differences 
in mean birth weight and gestational age compared with 
fathers without MS. Bearing in mind the lack of data, it 
seems reasonable for male MS patients to continue DMT 
during the conception period. Only treatment with mitox-
antrone, as mentioned above, should be stopped 6 months 
before pregnancy.
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Conclusion
Managing MS medication is a challenge, particularly when 
patients are pregnant or breastfeeding. For drugs that have 
been available for decades, such as IFN-β and GA, there is 
an increasing amount of information from pregnancy regis-
tries and observational studies. For new medications, such as 
DMF or teriflunomide, significantly less data are available. 
Therefore, further documentation in pregnancy registries of 
(unplanned) pregnancies with in utero exposure to DMDs is 
urgently needed. Attending physicians need to stay informed 
about current findings in MS pregnancy studies to be able to 
provide their patients with individual counseling based on 
the current state of knowledge.
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